As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview


Cambridge Isotope Laboratories, Inc. Announces 13C Cascade Production Optimization at Ohio Plant

December 16, 2020

 

Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), recently began a significant capacity optimization of one of the production cascades at the 13C separation facility in Xenia, Ohio. This optimization, which began this past summer and is scheduled for completion in the summer of 2021, will increase the cascade’s 13production by 10%. This follows the most recent expansion completion earlier this year, which increased 13C production capacity by 25%.  

 

In response to increased demand for 13C and 13urea, our engineering team has been working on initiatives designed to provide the additional capacity required to ensure meeting our long-term contractual obligations for our customer demand” states Cliff Caldwell, CEO.  

 

As we work to increase our operations and capabilities for our customers we sometimes need to think creatively for better solutionsThis project is an example of using different problem-solving methods to achieve a better operating production cascade,” says Mike Steiger, VP of Project Engineering and Execution.  

 

CIL’s isotope-separation facility houses the world’s largest 13C and one of the world’s largest 18O isotope-separation facilities. This facility also has the world’s only commercial D2O enrichment columns. These factors allow CIL to continue to be the world’s leading producer of stable isotopes and stable isotope-labeled compounds for analytical and research applications. Having process control of stable isotope starting materials ensures inventory of needed synthetic precursors and allows tight control over the product quality demanded by CIL.  

 

Back to list
CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.